链结合剂修改为伊米达索皮里丁,以准RET激酶的可操作突变
Arunkranthi Maturi1, Vinay Pogaku1, Surendra Kumar1
1Gachon Institute of Pharmaceutical Science and Department of Pharmacy, College of Pharmacy, Gachon University Yeonsu-gu Incheon Republic of Korea kmh0515@gachon.ac.kr.
RSC medicinal chemistry
|September 17, 2025
概括
新的伊米达佐[1,2-a]氨酸衍生物显示出对RET原瘤基因的强烈抑制,这是各种癌症的关键驱动因素. 这些新型化合物有效地向RET突变和融合,为克服对现有疗法的耐药性提供了希望.
科学领域:
- 在瘤学瘤学.
- 药用化学 医学化学
- 分子生物学分子生物学
背景情况:
- RET原瘤基因是多种癌症类型的重要驱动因素.
- 现有的RET抑制剂面临的挑战是响应率和从突变获得的耐药性.
- 对于针对RET变化的新型治疗策略有着至关重要的需求.
研究的目的:
- 发现和描述新型RET抑制剂.
- 评估新化合物对临床相关的RET突变和融合的疗效.
- 研究新型抑制剂的结合方式和潜在心脏毒性.
主要方法:
- 合成和选替代的伊米达佐[1,2-a]里丁衍生物.
- 在体外酶分析以确定与RET变异相对应的IC50值.
- 诱导适合对接模拟以预测结合相互作用.
- 对化合物的心脏毒性评估.
主要成果:
- 鉴定了具有强大的RET抑制活性的新型伊米达佐[1,2-a]氨酸衍生物.
- 针对三个不同的RET点突变,获得了低纳米IC50值 (低至11nM).
- 对三个重要的RET合并有显著的抑制作用.
- 通过计算模拟阐明了结合模式,并评估了心脏毒性.
结论:
- 替代的伊米达佐[1,2-a]皮里丁衍生物代表了一个有前途的新类RET抑制剂.
- 这些化合物显示出克服与RET突变和融合相关的抗性机制的潜力.
- 需要进一步研究它们的治疗潜力和安全性.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Receptor Tyrosine Kinases
18.0K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
18.0K
Transducer Mechanism: Enzyme-Linked Receptors
3.9K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.9K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
M-Cdk Drives Transition Into Mitosis
6.3K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.3K


